webinar

Using open science to develop Pediatric Cancer Drugs

Supported by:

19 September 2017

Childhood brain tumours are genetically distinct from adult cancers and are not a focus area for drug development. M4K Pharma is pioneering a novel open science business model to address these unprecedented “high risk” targets for a fraction of the usual cost.

In this webinar, the speakers showcase how collaboration between patient groups, charities, and academia resulted in the development of small molecule inhibitors targeting high-grade diffuse intrinsic pontine glioma (DIPG) that forms in the brainstem and has a median patient survival time of 9-12 months.

The presenters are Alex Bullock, PhD from the Structural Genomics Consortium and Owen Roberts, CEO, M4K Pharma and Nobelex Biotech.

The rest of this content is restricted - login or subscribe free to access

Issue 2 2021Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.

Why subscribe? Join our growing community of thousands of industry professionals and gain access to:

  • quarterly issues in print and/or digital format
  • case studies, whitepapers, webinars and industry-leading content
  • breaking news and features
  • our extensive online archive of thousands of articles and years of past issues
  • ...And it's all free!

Click here to Subscribe today Login here

 


Send this to a friend